Biovail In Trouble With Shareholders Over Aplenzin
Two months after settling a securities class action for $138 million, pharmaceutical giant Biovail Corp. faces another potentially expensive shareholder suit, alleging it misled investors about documents it filed with the...To view the full article, register now.
Already a subscriber? Click here to view full article